Transcriptional response networks for elucidating mechanisms of action of multitargeted agents

Swinney, 2013, Phenotypic vs. target-based drug discovery for first-in-class medicines, Clin. Pharmacol. Ther., 93, 299, 10.1038/clpt.2012.236 Capdeville, 2002, Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug, Nat. Rev. Drug Discov., 1, 493, 10.1038/nrd839 Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat. Rev. Drug Discov., 3, 711, 10.1038/nrd1470 Hutchinson, 2011, High drug attrition rates: where are we going wrong?, Nat. Rev. Clin. Oncol., 8, 189, 10.1038/nrclinonc.2011.34 Arrowsmith, 2012, A decade of change, Nat. Rev. Drug Discov., 11, 17, 10.1038/nrd3630 Waring, 2015, An analysis of the attrition of drug candidates from four major pharmaceutical companies, Nat. Rev. Drug Discov., 14, 475, 10.1038/nrd4609 Hopkins, 2007, Network pharmacology, Nat. Biotechnol., 25, 1110, 10.1038/nbt1007-1110 Kitano, 2007, A robustness-based approach to systems-oriented drug design, Nat. Rev. Drug Discov., 6, 202, 10.1038/nrd2195 Lehár, 2009, Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nat. Biotechnol., 27, 659, 10.1038/nbt.1549 Lamb, 2006, The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 Iorio, 2010, Discovery of drug mode of action and drug repositioning from transcriptional responses, Proc. Natl. Acad. Sci. U. S. A., 107, 14621, 10.1073/pnas.1000138107 Khan, 2014, Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis, Bioinformatics, 30, i497, 10.1093/bioinformatics/btu456 Li, 2009, Drug discovery and natural products: end of an era or an endless frontier?, Science, 325, 161, 10.1126/science.1168243 Tao, 2014, Nature's contribution to today's pharmacopeia, Nat. Biotechnol., 32, 979, 10.1038/nbt.3034 Harvey, 2015, The re-emergence of natural products for drug discovery in the genomics era, Nat. Rev. Drug Discov., 14, 111, 10.1038/nrd4510 Shen, 2015, A new golden age of natural products drug discovery, Cell, 163, 1297, 10.1016/j.cell.2015.11.031 Buriani, 2012, Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future, J. Ethnopharmacol., 140, 535, 10.1016/j.jep.2012.01.055 Azmi, 2012, Can network pharmacology rescue neutraceutical cancer research?, Drug Discov. Today, 17, 807, 10.1016/j.drudis.2012.06.008 Pelkonen, 2014, Why is research on herbal medicinal products important and how can we improve its quality?, J. Tradit. Complement. Med., 4, 1, 10.4103/2225-4110.124323 Kibble, 2015, Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products, Nat. Prod. Rep., 32, 1249, 10.1039/C5NP00005J Yatkin, 2014, Novel lignan and stilbenoid mixture shows anticarcinogenic efficacy in preclinical pC-3M-luc2 prostate cancer model, PLoS ONE, 9, e93764, 10.1371/journal.pone.0093764 Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U. S. A., 102, 15545, 10.1073/pnas.0506580102 Iorio, 2013, Transcriptional data: a new gateway to drug repositioning?, Drug Discov. Today, 18, 350, 10.1016/j.drudis.2012.07.014 Qu, 2012, Applications of Connectivity Map in drug discovery and development, Drug Discov. Today, 17, 1289, 10.1016/j.drudis.2012.07.017 Jahchan, 2013, A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors, Cancer Discov., 3, 1364, 10.1158/2159-8290.CD-13-0183 Laenen, 2013, Finding the targets of a drug by integration of gene expression data with a protein interaction network, Mol. Biosyst., 9, 1676, 10.1039/c3mb25438k Wu, 2013, Drug repositioning framework by incorporating functional information, IET Syst. Biol., 7, 188, 10.1049/iet-syb.2012.0064 Quan, 2014, Elucidating pharmacological mechanisms of natural medicines by biclustering analysis of the gene expression profile: a case study on curcumin and Si-Wu-Tang, Int. J. Mol. Sci., 16, 510, 10.3390/ijms16010510 Iskar, 2013, Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding, Mol. Syst. Biol., 9, 662, 10.1038/msb.2013.20 Jin, 2012, A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy, Cancer Res., 72, 33, 10.1158/0008-5472.CAN-11-2333 Parkkinen, 2014, Probabilistic drug connectivity mapping, BMC Bioinformatics, 15, 113, 10.1186/1471-2105-15-113 Pritchard, 2013, Predicting cancer drug mechanisms of action using molecular network signatures, Mol. Biosyst., 9, 1604, 10.1039/c2mb25459j Napolitano, 2016, Drug-set enrichment analysis: a novel tool to investigate drug mode of action, Bioinformatics, 32, 235, 10.1093/bioinformatics/btv536 Hegde, 2016, Unravelling druggable signalling networks that control F508del-CFTR proteostasis, eLife, 4, e10365, 10.7554/eLife.10365 Woo, 2015, Elucidating Compound mechanism of action by network perturbation analysis, Cell, 162, 441, 10.1016/j.cell.2015.05.056 Kullback, 1951, On information and sufficiency, Ann. Math. Stat., 22, 79, 10.1214/aoms/1177729694 Cichonska, 2015, Identification of drug candidates and repurposing opportunities through compound-target interaction networks, Expert Opin. Drug Discov., 10, 1333, 10.1517/17460441.2015.1096926 Tang, 2014, Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis, J. Chem. Inf. Model., 54, 735, 10.1021/ci400709d Huang, 2006, Molecular mechanisms of (−)-gossypol-induced apoptosis in human prostate cancer cells, Anticancer Res., 26, 1925 Volate, 2010, Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells, Mol. Cancer Ther., 9, 461, 10.1158/1535-7163.MCT-09-0507 Chen, 2011, Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma, PLoS ONE, 6, e27186, 10.1371/journal.pone.0027186 Gil-Ad, 2006, Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth, Oncol. Rep., 15, 107 Dorsam, 2007, G-protein-coupled receptors and cancer, Nat. Rev. Cancer, 7, 79, 10.1038/nrc2069 Berchtold, 2014, The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer, Biochim. Biophys. Acta, 1843, 398, 10.1016/j.bbamcr.2013.10.021 Dizeyi, 2005, Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines, Eur. Urol., 47, 895, 10.1016/j.eururo.2005.02.006 MacLean-Fletcher, 1980, Mechanism of action of cytochalasin B on actin, Cell, 20, 329, 10.1016/0092-8674(80)90619-4 Dodou, 2005, Investigations on gossypol: past and present developments, Expert Opin. Investig. Drugs, 14, 1419, 10.1517/13543784.14.11.1419 Lee, 2006, Involvement of nuclear factor-kappaB in the inhibition of pro-inflammatory mediators by pinosylvin, Planta Med., 72, 801, 10.1055/s-2006-941545 Laavola, 2015, Pinosylvin and monomethylpinosylvin, constituents of an extract from the knot of Pinus sylvestris, reduce inflammatory gene expression and inflammatory responses in vivo, J. Agric. Food Chem., 63, 3445, 10.1021/jf504606m Deeb, 2004, Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation, Mol. Cancer Ther., 3, 803, 10.1158/1535-7163.803.3.7 Allison, 2001, Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease, Prog. Neuropsychopharmacol. Biol. Psychiatry, 25, 1341, 10.1016/S0278-5846(01)00192-0 Boridy, 2014, Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells, Cell Death Dis., 5, e1216, 10.1038/cddis.2014.182 Sha, 2013, Celastrol induces apoptosis of gastric cancer cells by miR-146a inhibition of NF-κB activity, Cancer Cell Int., 13, 50, 10.1186/1475-2867-13-50 Lee, 2006, Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid, Biochem. Pharmacol., 72, 1311, 10.1016/j.bcp.2006.08.014 Tomé-Carneiro, 2013, Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence, Curr. Pharm. Des., 19, 6064, 10.2174/13816128113199990407 Chowdhury, 2005, Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids, Anticancer Res., 25, 2055 Carter, 2014, Resveratrol and cancer: focus on in vivo evidence, Endocr. Relat. Cancer, 21, R209, 10.1530/ERC-13-0171 Arango, 2013, Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets, Proc. Natl. Acad. Sci. U. S. A., 110, E2153, 10.1073/pnas.1303726110 Nam, 2006, Naturally occurring NF-kappaB inhibitors, Mini Rev. Med. Chem., 6, 945, 10.2174/138955706777934937 Lee, 2014, Inhibitory effects of resveratrol on melanin synthesis in ultraviolet B-induced pigmentation in Guinea pig skin, Biomol. Ther., 22, 35, 10.4062/biomolther.2013.081 Vahid, 2015, The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review, Gene, 562, 8, 10.1016/j.gene.2015.02.045 Place, 2005, HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha, Biochem. Pharmacol., 70, 394, 10.1016/j.bcp.2005.04.030 Merkle, 2011, Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor, Cell. Signal., 23, 507, 10.1016/j.cellsig.2010.08.017 Zivadinovic, 2005, Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses, Breast Cancer Res., 7, R101, 10.1186/bcr958 Park, 2012, Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases, Cell, 148, 421, 10.1016/j.cell.2012.01.017 Hamilton, 2013, Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer, World J. Urol., 31, 325, 10.1007/s00345-012-0848-7 Drees, 1993, 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition, Cancer Res., 53, 3058 Liu, 2006, Genistein acutely stimulates insulin secretion in pancreatic beta-cells through a cAMP-dependent protein kinase pathway, Diabetes, 55, 1043, 10.2337/diabetes.55.04.06.db05-1089 Hsieh, 1998, Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo, Cancer Res., 58, 3833 Park, 2013, Suppression of Src/ERK and GSK-3/β-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells, Food Chem. Toxicol., 55, 424, 10.1016/j.fct.2013.01.007 Prossnitz, 2015, International Union of Basic and Clinical Pharmacology. XCVII. G protein-coupled estrogen receptor and its pharmacologic modulators, Pharmacol. Rev., 67, 505, 10.1124/pr.114.009712 Ahola, 2002, Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells, Eur. J. Biochem., 269, 2485, 10.1046/j.1432-1033.2002.02912.x Chan, 2010, Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest, Cell Death Differ., 17, 1511, 10.1038/cdd.2010.20 Lam, 2014, Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer, Endocr. Relat. Cancer, 21, 903, 10.1530/ERC-14-0402 Mahmoud, 2014, Soy isoflavones and prostate cancer: a review of molecular mechanisms, J. Steroid Biochem. Mol. Biol., 140, 116, 10.1016/j.jsbmb.2013.12.010 Han, 2015, Anti-tumor effects and cellular mechanisms of resveratrol, Drug Discov. Ther., 9, 1, 10.5582/ddt.2015.01007 Iorio, 2015, A semi-supervised approach for refining transcriptional signatures of drug response and repositioning predictions, PLoS ONE, 10, e0139446, 10.1371/journal.pone.0139446 Ryall, 2015, Systems biology approaches for advancing the discovery of effective drug combinations, J. Cheminformatics, 7, 7, 10.1186/s13321-015-0055-9 Bulusu, 2015, Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives, Drug Discov. Today, 21, 225, 10.1016/j.drudis.2015.09.003 Tang, 2015, What is synergy? The Saariselkä agreement revisited, Exp. Pharmacol. Drug Discov., 6, 181 Iorio, 2009, Identifying network of drug mode of action by gene expression profiling, J. Comput. Biol. J. Comput. Mol. Cell Biol., 16, 241, 10.1089/cmb.2008.10TT Frey, 2007, Clustering by passing messages between data Points, Science, 315, 972, 10.1126/science.1136800 Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res., 13, 2498, 10.1101/gr.1239303 Khan, 2012, Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs, BMC Bioinformatics, 13, 112, 10.1186/1471-2105-13-112 Carrella, 2014, Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis, Bioinformatics, 30, 1787, 10.1093/bioinformatics/btu058 Gaulton, 2012, ChEMBL: a large-scale bioactivity database for drug discovery, Nucleic Acids Res., 40, D1100, 10.1093/nar/gkr777 Wishart, 2006, DrugBank: a comprehensive resource for in silico drug discovery and exploration, Nucleic Acids Res., 34, D668, 10.1093/nar/gkj067 Huang, 2006, Benchmarking sets for molecular docking, J. Med. Chem., 49, 6789, 10.1021/jm0608356 Irwin, 2005, ZINC: a free database of commercially available compounds for virtual screening, J. Chem. Inf. Model., 45, 177, 10.1021/ci049714+ Cerami, 2011, Pathway Commons, a web resource for biological pathway data, Nucleic Acids Res., 39, D685, 10.1093/nar/gkq1039 Jarvis, 1994, Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C, Cancer Res., 54, 1707 Finlayson, 2009, A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis, PLoS ONE, 4, e7833, 10.1371/journal.pone.0007833 Kim, 2014, Cytochalasin B modulates macrophage-mediated inflammatory responses, Biomol. Ther., 22, 295, 10.4062/biomolther.2014.055 Kannaiyan, 2011, Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer, Cancer Lett., 303, 9, 10.1016/j.canlet.2010.10.025 Virtanen, 2012, Bayesian group factor analysis, Proc. AISTATS. J. Mach. Learn. Res. W&CP, 22, 1269